TrialRheumatology (Oxford, England)2022

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.

Victoria P Werth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.